Owen Biosciences' over-the-counter benzoyl peroxide acne lotion had over 20 parts per million benzene and lacked release testing.
What happened
FDA inspected Owen Biosciences' drug manufacturing facility in Baton Rouge, LA, from March 25 to 27, 2025. FDA found the firm did not establish adequate laboratory controls or test each batch before release, including no benzene testing on benzoyl peroxide OTC products; FDA's lab found more than 20 parts per million (ppm) benzene in one lot of 2.5% benzoyl peroxide acne lotion. FDA also found an inadequate stability program and inadequate quality unit oversight, and the firm and distributor did not recall the tested lot before it expired.
What FDA found
The firm lacked scientifically sound specifications and final batch laboratory testing before release, and it did not test benzoyl peroxide products for benzene; FDA found more than 20 ppm benzene in one lot.
21 CFR 211.160(b) and 211.165(a)The firm's stability program was inadequate: full shelf-life studies were not done, and testing lacked identity, microbiological, and impurity tests.
21 CFR 211.166(a)The quality control unit did not adequately oversee manufacturing, including batch record review, investigation of discrepancies, change control, and annual product review.
21 CFR 211.22, 211.192, 211.180(e)After FDA recommended removal, the distributor said it would voluntarily recall the tested lot, but neither Owen nor the distributor recalled it before expiration.
What FDA wants
FDA tells Owen to respond in writing within 15 working days with corrective actions and supporting information. It asks for product specifications and test methods, a benzene test method, retain-sample testing and risk actions, a stability-program assessment and correction plan, an independent lab-system assessment, quality unit improvements, and a qualified current good manufacturing practice (CGMP) consultant.
Who should pay attention
- brands and distributors selling Owen-made OTC acne products
- contract manufacturers of OTC topical drugs
- quality and recall teams handling benzoyl peroxide products
This is a summary. Read the original letter on fda.gov.